Quick Answer
Mereo BioPharma Group plc reported Cash and Equivalents of $40.99 million for fiscal year 2025.
Mereo BioPharma Group plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $40.99M | -41.3% |
| 2024 | $69.80M | +21.6% |
| 2023 | $57.42M | -15.8% |
| 2022 | $68.18M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.70M | -39.5% | -13.2% |
| June 30, 2025 | $56.12M | -35.8% | -10.2% |
| March 31, 2025 | $62.48M | +28.4% | -10.5% |
| December 31, 2024 | $69.80M | +21.6% | -13.3% |
| September 30, 2024 | $80.52M | — | -7.9% |
| June 30, 2024 | $87.43M | — | +79.7% |
| March 31, 2024 | $48.66M | — | -15.3% |
| December 31, 2023 | $57.42M | — | — |
- Mereo BioPharma Group plc showed a decrease of -41.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Mereo BioPharma Group plc’s cash and equivalents has declined by 39.9% (from $68.18 million to $40.99 million).
- The most recent figure is from Mereo BioPharma Group plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: